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Objectives: To assess the cost-effectiveness of simeprevir (SMV) plus peginter-
feron/ribavirin (PR) versus triple therapy regimens of boceprevir (BOC)/PR and 
telaprevir (TVR)/PR and PR dual therapy in treatment-naïve and treatment-expe-
rienced patients, chronically infected with hepatitis C virus (HCV) genotype 1, in 
Colombia. MethOds: A lifetime Markov model, applying a generally accepted 
structure, was used to estimate disease progression of HCV patients aged 50 years. 
Dosage regimens, including response-guided therapy were based on the approved 
labels for each product. Sustained viral response rates, were obtained from a mixed 
treatment comparison. Costs were estimated from health care system perspec-
tive and are expressed in local currency (COP). A review of the literature to obtain 
epidemiologic and resource utilization data was performed and when data were 
not available or validation was needed a Delphi panel with local experts was car-
ried out. Primary outcomes included discounted quality adjusted life years (QALYs) 
and costs. Deterministic and probabilistic sensitivity analyses were performed to 
assess uncertainty. Results: Treatment-naïve: In comparison with TVR/PR, BOC/
PR and PR, SMV/PR incurred 0.133, 0.171 and 0.858 additional QALYs, respectively. 
SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are 
gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-
mated at COP 22,984,021/QALY. Treatment experienced: In comparison with TVR/
PR, BOC/PR and PR, SMV/PR increased QALYs by 0.043, 0.133 and 1.064, respectively. 
SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are 
gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-
mated at COP 22,437,019/QALY. These results were robust in the sensitivity analy-
ses. cOnclusiOns: SMV/PR dominated TVR/PR and BOC/PR, and is a cost-effective 
treatment option against WHO 3x GDP criteria in comparison to PR alone for treat-
ment-naïve and treatment-experienced genotype 1 HCV patients in Colombia.
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Objectives: To assess the cost-effectiveness of simeprevir plus sofosbuvir +/- riba-
virin (SMV/SOF) versus sofosbuvir plus peginterferon/ribavirin (SOF/PR) and SOF/R 
regimens in treatment-naïve (METAVIR F3-F4) and prior-null-responder patients 
(F0-F4) infected with genotype 1 HCV in the Dominican Republic (DR). MethOds: 
A Markov model, based on existing cost-effectiveness analyses, was applied to esti-
mate disease progression of a cohort of genotype 1 HCV patients aged 47.8 years 
over a life time horizon. Sustained viral response (SVR) rates were obtained from 
the COSMOS study for SMV/SOF, from NEUTRINO for SOF/PR and from SPARE and 
QUANTUM for SOF/R. SVR rates for SOF/R and SOF/PR in null responder patients 
were conservatively assumed equal to treatment-naïve patients. Patient baseline 
characteristics, mortality, discount rates and unit costs were obtained from local 
sources. HCV progression rates and health related quality of life estimates were 
based on literature and HCV cost-effectiveness models. Various sensitivity and 
scenario analyses were conducted to assess uncertainty around the estimated dis-
counted quality adjusted life years (QALYs) and costs. Results: In the treatment-
naïve patient population, SMV/SOF accrued 0.59 more QALYs and incurred $330,982 
less costs per patient compared to SOF/R, resulting in SMV/SOF as the dominant 
treatment option. Compared to SOF/PR, SMV/SOF accrued 0.08 additional QALYs 
and $52,319 additional costs resulting in a cost-effectiveness ratio of $626,676 and 
was cost-effective against WHO 3GDP criteria. In the prior-null-responder popula-
tion, SMV/SOF dominated both comparators. Multivariate probabilistic sensitivity 
analyses showed that at a willingness-to-pay of $1,000,000, the probability of SMV/
SOF being cost-effective was estimated at 62% and 92% in the treatment-naïve and 
prior null responder population, respectively. cOnclusiOns: SMV/SOF provides 
higher efficacy compared to its competitors, especially for patients that are more 
difficult to treat (prior null responders). Compared to SOF/R and SOF/PR, SMV/SOF 
represents a cost-effective treatment option to treat genotype 1 HCV patients in DM.
INfECtIoN – Patient-reported outcomes & Patient Preference studies
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ObjetivOs: O protocolo para HIV/AIDS do Ministério da Saúde brasileiro garante 
acesso universal ao tratamento para as pessoas infectadas por esse vírus (BRASIL, 
2013). Os esquemas iniciais, preferencialmente recomendados, permanecem con-
stituídos por dois inibidores de Transcriptase reversa análogo de nucleosídeos 
(zidovudina+lamivudina) e um inibidor de transcriptase reversa não-análogo de 
nucleosídeos (efavirenz). Neste sentido, este trabalho, buscou determinar a adesão 
dos pacientes à primeira linha antirretroviral dessa tratativa. MétOdOs: Estudo 
longitudinal com 100 pacientes em Acompanhamento Farmacoterapêutico (AFT), 
utilizando o Método Dáder, atendidos em um Centro de Especialidades Médicas em 
Fortaleza-CE, no período de novembro/2008 a agosto/2012. Os dados foram anali-
sados em SPSS. Estudo aprovado pelo Comitê de Ética – Universidade Federal do 
Ceará (Protocolo Nº 191/08). ResultAdOs: Durante o AFT obteve-se média de 1,41 
esquemas/paciente, com uma mediana de 1,00; desvio padrão de 0,79 e máximo 
de 05 mudanças de esquemas de antirretrovirais. Na primeira linha, foram prescri-
tos 15 diferentes tipos de esquemas antirretrovirais. A adesão global ao protocolo 
governamental foi de 79%, sendo de 44%(44/100) a adesão ao padrão: (zidovudina 
+ lamivudina) + efavirenz, seguido do esquema alternativo envolvendo os inibi-
dores de protease lopinavir/ritonavir agregado aos inibidores nucleosídeos da 
transcriptase reversa zidovudina/lamivudina, em 25% (25/100) do total na primeira 
escolha. Observou-se que a lamivudina esteve presente na totalidade das escolhas 
en el número de casos de dengue reportados en Colombia. ResultAdOs: Al utilizar 
como referencia el criterio de la OMS para evaluar intervenciones en salud, incluy-
endo en el análisis el efecto indirecto de la vacunación y ajustando el número de 
casos de dengue reportados por el subregistro, se identifica que si la vacunación 
inicia en un periodo epidémico —desde la perspectiva del tercer pagador— el precio 
máximo por dosis para que la intervención sea costo-efectiva es US$ 65,61 si la 
vacuna es aplicada a la población en riesgo de nueve años; US$ 66,65 si se aplica en la 
población entre los nueve y diecisiete años; y US$ 33,37 vacunando a la población de 
nueve o más años. cOnclusiOnes: Estos resultados permiten identificar el precio 
máximo para que la intervención sea costo-efectiva considerando niveles de protec-
ción indirecta de la vacunación sobre los no-vacunados y considerando el ajuste 
por el subregistro en el número de casos reportados. Estos resultados representan 
la primera ocasión en que la vacuna contra el dengue de Sanofi Pasteur es evaluada 
a través de los resultados de eficacia obtenidos en su fase III en América Latina.
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Objectives: To assess the cost-effectiveness and cost-utility of simeprevir (SMV) 
plus peginterferon/ribavirin (PR) versus boceprevir (BOC)/PR in treatment-naïve 
patients [METAVIR F0-F3], versus PR in treatment-naïve [F0-F3 and F4] and treat-
ment-experienced patients in partial and null responders [F0-F4], and versus 
“no treatment” in treatment-experienced patients [F0-F4], chronically infected 
with hepatitis C virus (HCV) genotype 1, in Mexico. MethOds: A lifetime Markov 
model, was used to estimate disease progression for treatment-naïve and treat-
ment-experienced patients aged 47.8 years. Dosage regimens, including response-
guided therapy and futility stopping rules, were based on Mexican HCV treatment 
guidelines. Sustained viral response rates were obtained from relevant phase II/
III clinical trials. Patient baseline characteristics, mortality, discount rates and 
unit costs were obtained from local sources and an advisory board. HCV pro-
gression rates and health related quality of life estimates were based on pub-
lished literature and HCV cost-effectiveness models. Sensitivity analyses were 
conducted to estimate discounted quality adjusted life years (QALYs) and costs 
(in Mexican pesos). Results: In the treatment-naïve, F0-F3 population, SMV/PR 
was the dominant alternative, accruing more QALYs and less costs per patient 
compared to BOC/PR and PR alone (11.25 vs 11.08 and 10.67; $348,355 vs $455,709 
and $368,416, respectively). Likewise, SMV/PR was the dominant treatment option 
when compared with PR alone in the treatment-naïve, F4 population (7.43 vs 
6.85 QALYs; $668,475 vs $731,854, respectively) and treatment-experienced (9.27 
vs 8.42; $559,697 vs $609,751, respectively). Compared to “no treatment”, more 
costs and more QALYs were accumulated resulting in an incremental cost-utility 
ratio of $43,116 in the treatment-experienced population. Multivariate proba-
bilistic sensitivity analyses showed that at a willingness-to-pay threshold of 
$100,000, the probability that SMV/PR is cost-effective was > 80% for all treat-
ment groups. cOnclusiOns: SMV/PR appears a cost-effective treatment option 
in genotype 1 HCV patients compared to other regimens currently available in 
Mexico, regardless of treatment experience and fibrosis.
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Objectives: The prevention, diagnosis and treatment of chronic hepatitis C inte-
grates health policies in Brazil and worldwide. This disease affect many people, 
features high cost treatment and cause severe outcomes and disability, increasing 
social cost. We performed a cost-effectiveness analysis under the perspective of 
SUS, with the following strategies: treatment and retreatment with dual therapy, 
treatment with dual therapy and retreatment with triple therapy and treatment 
with triple therapy. MethOds: A Markov model was developed with a hypotheti-
cal cohort of 1000 adults, over 40 years, of both sexes, with confirmed diagnosis for 
chronic hepatitis C, monoinfected by HCV genotype 1 and absence of comorbidities.
The simulation started with all individuals carrying the milder form of the disease, 
considered F0 or F1, according to Metavir histological classification. Results: 
The results demonstrate the dual/triple therapy and triple therapy are below the 
acceptable threshold for embedding technology proposed by the WHO. Both are 
cost-effective. ICER of dual/triple therapy compared with base line was 7186.3 (R$/
QALY) and the triple therapy compared with dual/triple therapy was 59053.8 (R$/
QALY). However, the incremental cost of triple therapy compared to dual/triple 
therapy was 31029 and incremental effectiveness was 0.52. Triple therapy, despite 
having a little more effectiveness than the dual/triple therapy, showed much high-
ercost. cOnclusiOns: Thus, as would be consistent adopt one or the other for use 
in the SUS, since this system has limited resources, is better indicate the realization 
a budget impact analysis to have one more data information to support the decision 
to continue adopting the Brazilian guideline existing or suggest making another one.
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